Journal of Oncology Pharmacy Practice This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant
Conclusions Further studies are suggested to investigate the optimal number and timing of doses of fosaprepitant in this setting. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Clark, S. M., Clemmons, A. B., Schaack, L., Garren, J., DeRemer, D. L., Kota, V. K. Tags: Original Articles Source Type: research

Development of a combination antibiogram for Pseudomonas aeruginosa bacteremia in an oncology population
Conclusions Effective combination regimens included all beta-lactam aminoglycoside regimens. Receipt of IV antibiotics within 90 days and hospital LOS greater than or equal to five days were independent risk factors for MDR isolates. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Smith, Z. R., Tajchman, S. K., Dee, B. M., Bruno, J. J., Qiao, W., Tverdek, F. P. Tags: Original Articles Source Type: research

Detection of 5-fluorouracil surface contamination in near real time
In this report, we describe the laboratory performance of a 5-fluorouracil (5-FU) monitor. Methods The monitor was evaluated by spiking ceramic, vinyl, composite, stainless steel, and glass surfaces of 100 cm2 area with 5-FU masses of 0, 5, 10, 25, 50, and 100 ng. The surface was sampled with a wetted cotton swab, the swab was extracted with buffer, and the resulting solution was applied to a lateral flow monitor. Two ways of evaluating the response of these monitors were used: an electronic method where a lateral flow reader was used for measuring line intensities, and a visual method where the intensity of the test line...
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Smith, J. P., Sammons, D. L., Pretty, J. R., Kurtz, K. S., Robertson, S. A., DeBord, D. G., Connor, T. H., Snawder, J. E. Tags: Original Articles Source Type: research

'Acceptability of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia
Conclusion The results of this survey show that Xaluprine® has good overall acceptability in the paediatric population and suggests that Xaluprine® is an important, alternative, age-appropriate formulation of mercaptopurine. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Mulla, H., Buck, H., Price, L., Parry, A., Bell, G., Skinner, R. Tags: Original Articles Source Type: research

Abstracts
(Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - April 18, 2016 Category: Cancer & Oncology Tags: Abstracts Source Type: research

Generic imatinib in the treatment of chronic myeloid leukemia: Cerrahpasa experience
As the first tyrosine kinase inhibitor (TKI), imatinib (Gleevec or Glivec, Novartis Pharmaceuticals) was introduced, the treatment of chronic myeloid leukemia (CML) has changed radically, and the TKIs are now the mainstay of CML treatment. The substantially high treatment cost has unfortunately been a major issue, which puts a strain on health-care budgets even in developed countries. So reimbursement policies encourage generic drug (i.e. generic imatinib) use to lower the expenses, and it is true that generics would lead to considerable cost savings, but they also give rise to questions associated with their efficacy, saf...
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Eskazan, A. E., Soysal, T. Tags: Commentary Source Type: research

Medication adherence to oral cancer therapy: The promising role of the pharmacist
Medication adherence to oral cancer therapy is a critical component to achieving optimal patient outcomes. As the US population ages, growing numbers of patients will be prescribed oral cancer therapy regimens, highlighting the need for innovative and scalable solutions. Clinical pharmacists offer tremendous promise to help patients improve their adherence to oral cancer therapy. Moreover, addition of oral chemotherapy to Centers for Medicare & Medicaid Services (CMS) medication adherence quality measures has the potential to improve care and result in better therapeutic outcomes with fewer costs for patients and payer...
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Felton, M. A., van Londen, G., Marcum, Z. A. Tags: Commentary Source Type: research

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy
We report a woman treated with chemotherapy and imatinib mesylate who delivered a healthy baby at 30 weeks, and we discuss available data. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Mainor, C. B., Duffy, A. P., Atkins, K. L., Kimball, A. S., Baer, M. R. Tags: Case Reports Source Type: research

Initiation of exemestane in two warfarin-treated patients leading to elevation and variability of INR
We report two cases where patients on warfarin therapy had an increase in their international normalized ratio with the initiation of exemestane therapy. Initially, the patients also showed international normalized ratio variability possibly due to variable absorption of exemestane. We suggest patients being treated with warfarin and exemestane concomitantly need close monitoring and education in order to decrease the risk of adverse events that could be associated with this possible interaction. To our knowledge, there are no similar reported cases in the literature. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Dush, A., Williams, A., Mangini, N., Klaczak, K. Tags: Case Reports Source Type: research

Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate
In this study, we describe two patients with Philadelphia chromosome-positive hematological malignancies who presented with secondary thrombotic microangiopathy that was most likely linked to the use of imatinib. Other potential causes of thrombotic microangiopathy were discarded, and the predisposing role of some comorbidities and potential short or long-term drug–drug interactions was assessed. The clinical and biological data were more indicative of atypical secondary hemolytic uremic syndrome in one of the cases and of secondary thrombotic microangiopathy with renal and cardiac impairment in the other, which is a...
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Ojeda-Uribe, M., Merieau, S., Guillon, M., Aujoulat, O., Hinschberger, O., Eisenmann, J.-C., Kenizou, D., Debliquis, A., Veyradier, A., Chantrel, F. Tags: Case Reports Source Type: research

A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use
We report a case suggesting crystal nephropathy as the mechanism for acute kidney injury in pomalidomide and fluoroquinolone use. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Baird, P., Leung, S., Hoang, H., Babalola, O., Devoe, C. E., Wanchoo, R., Jhaveri, K. D. Tags: Case Reports Source Type: research

Successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia
We report a case in which a child with very high-risk ALL having experienced severe anaphylaxis with pegaspargase was later successfully treated with palifermin during stem cell transplant conditioning. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Kaminski, K. S., Beach, C. L., Peden, D. B., Le, U., Roehrs, P. A. Tags: Case Reports Source Type: research

Sorafenib-induced severe urticaria in a patient with hepatocellular cancer
Sorafenib which is used in the treatment of renal, thyroid and hepatocellular cancers is a multi-targeted tyrosine kinase inhibitor. Though sorafenib is associated with some side effects, it is known that sorafenib is generally well tolerated compared to other tyrosine kinase inhibitors. In the present case, hepatocellular cancer was diagnosed seven months ago. The disease was in stage IIIB at the time of diagnosis. Sorafenib was initiated with a dose of 400 mg twice daily because of disease progression after two cycles of doxorubicin. The reactions on the skin of the arms and the body of the patient occurred in the eighth...
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Musri, F. Y., Mutlu, H., Kıvrak Salim, D., Karakurt Eryılmaz, M., Ünal, B., Tural, D., Senol Coskun, H. Tags: Case Reports Source Type: research

A case report of three patients with metastatic gastric cancer on hemodialysis who were treated with cisplatin-fluorouracil regimen
Gastric carcinoma is the first cause of death worldwide. In previous studies that included best supportive care and chemotherapy comparison, chemotherapy survival time was four to five months more than best supportive care. This time was reported as seven to nine months in cisplatin and fluorouracil therapy. We aimed to call attention to non-progression survival time which was being longer with cisplatin and fluorouracil therapy in three metastatic gastric carcinoma patients who were on hemodialysis due to chronic renal impairment related to diabetic nephropathy. We determined that this regimen was well tolerated with hemo...
Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Tanriverdi, O., Ogunc, H. Tags: Case Reports Source Type: research